Open Access
| Issue |
BIO Web Conf.
Volume 240, 2026
The 2026 International Conference on Biomedicine, Neuroscience and Biostatistics (ICBNB 2026)
|
|
|---|---|---|
| Article Number | 01028 | |
| Number of page(s) | 4 | |
| Section | Biomedicine, Neuroscience and Biostatistics | |
| DOI | https://doi.org/10.1051/bioconf/202624001028 | |
| Published online | 24 June 2026 | |
- H. Sung, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71, 209–249 (2021) [CrossRef] [PubMed] [Google Scholar]
- R. Ghemrawi, Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines. 12, 9 (2024) [Google Scholar]
- P. Plewa, mRNA Vaccines in Melanoma Immunotherapy-A Narrative Review. Cells. 15, 3 (2026) [Google Scholar]
- Y. Muto, T. Fujimura, Y.Asano, Recent Advances in Immunotherapy for Melanoma: Perspectives on the Development of Novel Treatments: A Mini Review. Cancers. 17, 13 (2025) [Google Scholar]
- M.Z. Wojtukiewicz, Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 40, 949 (2021) [Google Scholar]
- J. Wei, Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. Mol Cancer. 23, 279 (2024) [Google Scholar]
- B. Kong, mRNA: A promising platform for cancer immunotherapy. Adv Drug Deliv Rev. 199, 114993 (2023) [Google Scholar]
- X. Hou, Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 6, 1078 (2021) [CrossRef] [Google Scholar]
- T. Huang, Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol. 13, 922301 (2022) [Google Scholar]
- G. He, Advancements in melanoma immunotherapy: the emergence of Extracellular Vesicle Vaccines. Cell Death Discov. 10, 374 (2024) [Google Scholar]
- Y. Liang, Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment. Front Immunol. 16, 1691608 (2025) [Google Scholar]
- J.S. Weber, Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 403, 632 (2024) [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.